Indivior’s (INDV) Outperform Rating Reiterated at Royal Bank Of Canada

Indivior (LON:INDV)‘s stock had its “outperform” rating reissued by research analysts at Royal Bank Of Canada in a research note issued to investors on Friday. They currently have a GBX 500 ($6.70) price target on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 24.72% from the company’s current price.

A number of other research analysts have also recently commented on INDV. Morgan Stanley reiterated an “equal weight” rating and issued a GBX 410 ($5.49) price objective on shares of Indivior in a report on Friday. Stifel Nicolaus restated a “buy” rating and set a GBX 400 ($5.36) target price on shares of Indivior in a report on Friday, September 15th. Citigroup reissued a “neutral” rating and set a GBX 280 ($3.75) target price on shares of Indivior in a research note on Tuesday, September 5th. Numis Securities reiterated a “buy” rating and issued a GBX 500 ($6.70) price target on shares of Indivior in a report on Monday, October 30th. Finally, Jefferies Group raised their price objective on Indivior from GBX 358 ($4.79) to GBX 472 ($6.32) and gave the stock a “buy” rating in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of GBX 472.43 ($6.33).

Indivior (LON INDV) opened at GBX 400.90 ($5.37) on Friday. Indivior has a fifty-two week low of GBX 246.50 ($3.30) and a fifty-two week high of GBX 421.50 ($5.64).

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at

Indivior Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with's FREE daily email newsletter.

Leave a Reply